# Seres Therapeutics, Inc. (MCRB) — bankruptcy [announced]
Source: SEC API (secapi.ai) · situation sit_1a70582b6b97462f64ae · retrieved 2026-08-11T16:14:36.104Z

## Overview
Seres Therapeutics, Inc. is a pharmaceutical company that develops microbiome-based therapeutics; it leases office, laboratory, and manufacturing space in Cambridge, Massachusetts.

Seres Therapeutics, Inc. entered into a Third Amendment to Lease and Termination Agreement with BMR-Sidney Research Campus LLC on July 31, 2026, to effect an early termination of its lease at 200 Sidney Street, Cambridge, Massachusetts. The company will surrender approximately 21,295 rentable square feet effective August 1, 2026, and terminate the remaining 47,341 rentable square feet lease on December 31, 2026 (accelerated from January 13, 2031). As consideration, Seres agreed to: (i) increase the letter of credit by $2,238,415.84 (to a total of $3,638,415.84), which the landlord will apply toward rent and operating expenses through the lease expiration; (ii) pay a termination fee of $3,850,000 by January 4, 2027; and (iii) issue 103,520 shares of common stock valued at $500,001.60 (at the July 31, 2026 closing price of $4.83 per share), to be issued within five business days.

## Terms
- Counterparty: BMR-Sidney Research Campus LLC · Consideration: mixed · Price/share: $4.83

## Key dates
- Announced 2026-08-04 · Expected close 2026-12-31

## Timeline
- 2026-08-04 · 8-K (0001193125-26-332742): 8-K - Seres Therapeutics, Inc. — *Seres Therapeutics, Inc. is a pharmaceutical company that develops microbiome-based therapeutics; it leases office, laboratory, and manufacturing space in Cambridge, Massachusetts.* Seres Therapeutics, Inc. entered into a Third Amendment to Lease and Termination Agreement with BMR-Sidney Research Campus LLC on July 31, 2026, to effect an early termination of its lease at 200 Sidney Street, Cambridge, Massachusetts. The company will surrender approximately 21,295 rentable square feet effective August 1, 2026, and terminate the remaining 47,341 rentable square feet lease on December 31, 2026 (accelerated from January 13, 2031). As consideration, Seres agreed to: (i) increase the letter of credit by $2,238,415.84 (to a total of $3,638,415.84), which the landlord will apply toward rent and operating expenses through the lease expiration; (ii) pay a termination fee of $3,850,000 by January 4, 2027; and (iii) issue 103,520 shares of common stock valued at $500,001.60 (at the July 31, 2026 closing price of $4.83 per share), to be issued within five business days.
  https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-332742.txt

## Citations
- 0001193125-26-332742 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526332742